Relmada is a pharmaceutical company specializing in clinical-stage chronic pain therapies and treatments. It trades under the symbols OTCQB: RLMD. Recently, the company’s filed for an injunction against Laidlaw & Company (UK) Ltd. The U.S District Court for the Nevada District finally approved it and granted them a favorable ruling. The presiding judge ordered Laidlaw to cease releasing any further false information and materials regarding the complainant: Relmada Inc.
Gross Misconduct Charges
The first restraining order on the same matter was issued on December 10th 2015. It was reported that the accused were spreading fictitious materials with the intentions of taking over Relmada. Speaking at a press conference, the C.E.O said that his company would not bow to pressure from anyone. Their number one priority would remain to serve the interests of their stakeholders. Sergio Traversa heavily criticized Laidlaw for their unprofessional conduct.
Some Novel Therapies by Relmada
Much of the success of Relmada can be directly attributed to their impeccable strategizing. Over the years, the company has developed a solid multi-faceted strategy aimed at creating viable opportunities moving forward. For instance, they have been steadily working on BuTab. This is a novel treatment meant to deal with both chronic pain and opiate addiction.
Relmada held their annual stockholder’s meeting towards the end of 2005. In the meeting, it was decided that their lawyers should proceed onward with the mitigation case against the New York investment banker, Laidlaw.
About the Main Principals at Laidlaw
The C.E.O is Mathew D. Eitner. He first started working at Laidlaw at 2010. He ascended to the position in April 2011. His past work experiences include serving as the GM at Aegis Capital Corp. Previously, Matthew was the V.P at Casimir Capital. He had a short stint at Deutsche Bank. He was the banks’ Lead Equity trader. Mr. Eitner is also involved in a lot of charity work.
The Head of Capital Markets is known as Mr. James P. Ahern. His central docket deals with overseeing the financing of both the private and the public companies with their portfolios. Before joining Laidlaw, Mr. Ahern was the MD of the Aegis Capital Corp and the V.P at Casimir Capital. He’s also an avid philanthropist.